1. Brent RL. Environmental Causes of Human Congenital Malformations: The Pediatrician's Role in Dealing With These Complex Clinical Problems Caused by a Multiplicity of Environmental and Genetic Factors. PEDIATRICS 2004; 113 (4): 957–68.
2. Wilson JG. Current status of teratology. In: Wilson JG, Fraser FC, eds. Handbook of teratology. New York: Plenum, 1977; 47.
3. Mortensen ME, Sever LE, Oakley GP. Teratology and the epidemiology of birth defects. In: SG.Gabbe, JR.Niebyl, JL.Simpson (eds): Obstetrics: Normal and Problem Pregnancies. New York, Churchill Livingstone, 1991; 233–68.
4. Стриженок Е.А., Гудков И.В., Страчунский Л.С. Применение лекарственных средств при беременности: результаты многоцентрового фармакоэпидемиологического исследования. КМАХ. 2007; 9 (2): 162–75.
5. Amann U, Egen-Lappe V, Strunz-Lehner C, Hasford J. Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population. Pharmacoepidemiol Drug Saf 2006; 15: 327–37.
6. Miller EM. Changes in serum immunity during pregnancy. Am J Hum Biol 2009; 2.
7. Cartin-Ceba R, Gajic O, Iyer VN, Vlahakis NE. Fetal outcomes of critically ill pregnant women admitted to the intensive care unit for nonobstetric causes. Crit Care Med 2008; 36 (10): 2746–51.
8. Mann JR, McDermott S, Bao H, Bersabe A. Maternal genitourinary infection and risk of cerebral palsy. Dev Med Child Neurol 2009.
9. Herra´iz MA, Herna´ndez A, Asenjo E, Herra´iz I [Urinary tract infection in pregnancy]. Enferm Infecc Microbiol Clin 2005; 23 (Suppl. 4): 40–6.
10. Никонов А.П., Асцатурова О.Р., Шулутко П.А., Каптильный В.А. Инфекции мочевыводящих путей и беременность: диагностика и антибактериальная терапия. Consilium Medicum 2006; 6.
11. Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. Am J Obstet Gyn 2008; 198 (1): 7–2.
12. Kirkham C, Harris S, Grzybowski S. Evidence-based prenatal care: part II. Third-trimester care and prevention of infectious diseases. Am Fam Physician 2005; 71 (8): 1555–60.
13. Swadpanich U, Lumbiganon P, Prasertcharoensook W, Laopaiboon M. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database Syst Rev. 2008; 2: CD00617.
14. Amann U, Egen-Lappe V, Strunz-Lehner C, Hasford J. Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population. Pharmacoepidemiol Drug Saf 2006; 15: 327–37.
15. Рафальский В.В. Обоснование выбора антимикробных препаратов при амбулаторных инфекциях мочевыводящих путей. Дис. ... докт. мед. наук. Смоленск, 2004.
16. Gagne JJ, Maio V, Berghella V et al. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 2008; 64 (11): 1125–32.
17. Morency AM, Bujold E. The effect of second-trimester antibiotic therapy on the rate of preterm birth. J Obstet Gyn Can 2007; 29 (1): 35–44.
18. Rosental M. How safe is that antimicrobial you are writing for the female patient? Infectious disease news. 2003.
19. Haas A, Maschmeyer G. [Antibiotic therapy in pregnancy]. Dtsch Med Wochenschr 2008; 133 (11): 511–5.
20. Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gyn 2006; 107 (5): 1120–38.
21. Jepsen P, Skriver MV, Floyd A et al. A population-based study of maternal use of amoxicillin and pregnancy outcome in Denmark. Br J Clin Pharmacol 2003; 55 (2): 216–21.
22. Berkovitch M, Diav-Citrin O, Greenberg RC et al. First-trimester exposure to amoxycillin/clavulanic acid: a prospective, controlled study. Br J Clin Pharmacol 2004; 58 (3): 298–302.
23. Kenyon S, Pike K, Jones DR et al. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet 2008; 372 (9646): 1319–27.
24. Ka..lle´n BA, Otterblad Olausson P, Danielsson BR. Is erythromycin therapy teratogenic in humans? Reprod Toxicol 2005; 20 (2): 209–14.
25. Czeizel AE, Rockenbauer M, Olsen J, Sørensen HT. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gyn Scand 2000; 79 (3): 234–7.
26. Pitsouni E, Iavazzo C, Athanasiou S, Falagas ME. Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2007; 30 (3): 213–21.
27. European STD Guidelines, International J of STD AIDS 2001; 12 (Suppl. 3).
28. Российское общество акушеров-гинекологов. Информационное письмо. М., 2005.
29. Sarkar M, Woodland C, Koren G, Einarson AR. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth 2006; 6: 18.
30. Einarson A, Phillips E, Mawji F et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 1998; 15 (9): 523–5.
31. Guay DR. Contemporary management of uncomplicated urinary tract infections. Drugs 2008; 68 (9): 1169–205.
32. Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008; 14 (Suppl. 1): 198–202.
33. Bayrak O, Cimentepe E, Ineg_l I et al. Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimesterof pregnancy? Int Urogynecol J Pelvic Floor Dysfunct 2007; 18 (5): 525–9.
34. Naber KG, Schito G, Botto H et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008; 54 (5): 1164–75.
35. Синякова Л.А., Косова И.В. Применение фосфомицина трометамола в лечении инфекций нижних отделов мочевыводящих путей. Клин. микробиол. и антимикроб. xимиотер. 2005; 7 (2).
36. Reeves DS. Treatment of bacteriuria in pregnancy with single dose fosfomycin trometamol: a review. Infection 1992; 20 (Suppl. 4): S313–6.
37. Smet PA. Clinical risk management of herb-drug interactions. Br J Clin Pharmacol 2007; 63 (3): 258–67.
38. Boullata JI, Nace А. Safety Issues with Herbal Medicine. Pharmacotherapy 2000; 20 (3): 257–69.
39. Low Dog T. The use of botanicals during pregnancy and lactation. Altern Ther Health Med 2009; 15 (1): 54–8.
40. Monitoring of herbal medicines http://www.whoumc.org/DynPage.aspx?id=13120&mn=1510#herbal.
41. Gabardi S, Munz K, Ulbricht C. A review of dietary supplement-induced renal dysfunction. Clin J Am Soc Nephrol 2007; 2 (4): 757–65.
42. Lai RS, Chiang AA, Wu MT et al. Outbreak of bronchiolitis obliterans associated with consumption of Sauropus androgynus in Taiwan. Lancet 1996; 348: 83–5.